Send us Fan Mail

How do LATAM healthcare markets differ and what do these differences mean for Pharma and Medtech launch planning? What should global market access teams know to support affiliates in Argentina, Brazil, Colombia, and Mexico? How do evidence requirements, access routes, and payer expectations vary across the region?

For global market access teams planning for launch in Latin America (LATAM), understanding the diversity and complexity of this region is essential. Healthcare systems vary significantly between markets, regulatory and payer expectations differ, and health technology assessment (HTA) processes continue to evolve. These differences create both opportunities and challenges for Pharma and Medtech companies preparing evidence, developing global plans, and equipping local affiliates with the right materials to secure access.

In this episode, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed four regional experts:

• For Argentina: Eleonora Aiello (CEO at Ceibo Health Consulting)
• For Brazil: Alessandra Calabró (Independent expert in market access and government affairs)
• For Colombia: María Fernanda Escobar (Principal Advisor, InnovaSalud)
• For Mexico: Fernando del Río (Partner at InnovaSalud, GP at XB Ventures)

Together, they unpack the access landscape in their countries, sharing experience‑based insight to help global teams refine evidence plans and align global materials to local payer expectations.

Together, they explore:

• Variation in healthcare systems, regulatory structures, and payer landscapes across LATAM
• HTA landscape in key markets and the influence of bodies such as CONITEC in Brazil, IETS in Colombia, CENETEC in Mexico, and ANEFiTS in Argentina
• Differences in evidence expectations, including clinical, economic, and real‑world data requirements
• How global dossiers, value messages, and evidence packages can better support affiliates engaging with local payers
• Opportunities and challenges for introducing Pharma and Medtech innovations into LATAM markets
• Future policy, regulatory, and reimbursement developments to monitor across the region

This episode was first broadcast as a live webinar on Thursday 19th March 2026. For more information about this webinar see: https://petauri.com/insights/latam-market-access-unlocked/

For support with market access strategy and global launch, please reach out to evidence@petauri.com.

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us Fan Mail

What does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding?

In this Petauri Evidence NHS Whispers session, we put your questions to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS), as he shares how he and his colleagues are responding to the changing NHS environment. From system pressures and financial constraints to prescribing priorities and service redesign, Yousaf explored how ICS pharmacy teams are adapting, and what this means for industry partners.

This episode was first broadcast as live webinar on: Friday 24th October 2025.

Learn more about this episode at https://petauri.com/insights/evolving-nhs-ics-chief-pharmacists-perspective/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us Fan Mail

What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?

This episode explores Switzerland’s potential as an early launch market.

In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.

Together, we explored what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.

We discussed:
- What makes Switzerland attractive as a first-launch market
- Key differences between Swiss and European Union (EU) market access pathways
- How to prepare for inclusion on the SL and what “economically efficient pricing” really means
- The role of cantonal (state) variation and decentralised healthcare in shaping access
- How Swiss decisions may be influenced by the EU’s JCA
- What global teams can learn from Swiss strategy to inform broader launch planning

This episode was first broadcast as a live webinar on Thursday 16th October 2025

Learn more at https://petauri.com/insights/market-access-switzerland/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence